NasdaqGS - Nasdaq Real Time Price • USD
Moderna, Inc. (MRNA)
As of 3:05 PM EDT. Market Open.
Earnings Estimate
| CURRENCY IN USD | Current Qtr. (Jun 2024) | Next Qtr. (Sep 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 16 | 16 | 21 | 21 |
| Avg. Estimate | -3.13 | -1.01 | -6.65 | -4.91 |
| Low Estimate | -3.91 | -3 | -7.93 | -6.7 |
| High Estimate | -2.7 | -0.16 | -5.64 | -0.92 |
| Year Ago EPS | -3.62 | -9.53 | -11.47 | -6.65 |
Revenue Estimate
| CURRENCY IN USD | Current Qtr. (Jun 2024) | Next Qtr. (Sep 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 14 | 14 | 21 | 20 |
| Avg. Estimate | 130.32M | 1.41B | 3.84B | 4.39B |
| Low Estimate | 93.05M | 383.65M | 3.34B | 3.32B |
| High Estimate | 214.01M | 1.85B | 4.22B | 5.46B |
| Year Ago Sales | 344M | 1.83B | 6.37B | 3.84B |
| Sales Growth (year/est) | -62.10% | -23.20% | -39.70% | 14.10% |
Earnings History
| CURRENCY IN USD | 6/30/2023 | 9/30/2023 | 12/31/2023 | 3/31/2024 |
|---|---|---|---|---|
| EPS Est. | -4.04 | -1.93 | -0.9 | -3.34 |
| EPS Actual | -3.62 | -9.53 | 0.51 | -2.86 |
| Difference | 0.42 | -7.6 | 1.41 | 0.48 |
| Surprise % | 10.40% | -393.80% | 156.70% | 14.40% |
EPS Trend
| CURRENCY IN USD | Current Qtr. (Jun 2024) | Next Qtr. (Sep 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Current Estimate | -3.13 | -1.01 | -6.65 | -4.91 |
| 7 Days Ago | -3.23 | -1.02 | -6.81 | -5 |
| 30 Days Ago | -3.5 | -1 | -7.2 | -5.19 |
| 60 Days Ago | -3.32 | -1.08 | -7.1 | -4.97 |
| 90 Days Ago | -3.08 | -1.18 | -6.87 | -4.77 |
EPS Revisions
| CURRENCY IN USD | Current Qtr. (Jun 2024) | Next Qtr. (Sep 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Up Last 7 Days | 4 | 2 | 7 | 7 |
| Up Last 30 Days | 12 | 7 | 11 | 14 |
| Down Last 7 Days | -- | -- | -- | -- |
| Down Last 30 Days | -- | 2 | 2 | -- |
Growth Estimates
| CURRENCY IN USD | MRNA | Industry | Sector | S&P 500 |
|---|---|---|---|---|
| Current Qtr. | 13.50% | -- | -- | 7.40% |
| Next Qtr. | 89.40% | -- | -- | 10.80% |
| Current Year | 42.00% | -- | -- | 4.60% |
| Next Year | 26.20% | -- | -- | 13.20% |
| Next 5 Years (per annum) | -47.75% | -- | -- | 10.91% |
| Past 5 Years (per annum) | -- | -- | -- | -- |
Research Analysis
Upgrades & Downgrades
| Maintains | UBS: Buy to Buy | 5/7/2024 |
| Maintains | Canaccord Genuity: Hold to Hold | 5/3/2024 |
| Maintains | RBC Capital: Outperform to Outperform | 5/3/2024 |
| Maintains | Oppenheimer: Outperform to Outperform | 5/3/2024 |
| Reiterates | Needham: Hold | 5/2/2024 |
| Reiterates | Needham: Hold | 4/11/2024 |
Related Tickers
BNTX BioNTech SE
91.95
-0.12%
NVAX Novavax, Inc.
8.72
+95.08%
NVO Novo Nordisk A/S
128.67
+0.00%
VRTX Vertex Pharmaceuticals Incorporated
422.03
+0.73%
CRSP CRISPR Therapeutics AG
51.31
-4.18%
VKTX Viking Therapeutics, Inc.
74.40
-7.23%
REGN Regeneron Pharmaceuticals, Inc.
975.28
+0.75%
SAVA Cassava Sciences, Inc.
20.19
-4.38%
IBRX ImmunityBio, Inc.
8.01
-0.62%
DNA Ginkgo Bioworks Holdings, Inc.
0.7502
-18.46%